166 related articles for article (PubMed ID: 25218567)
1. [End of the commercialisation of (192)Ir wires in France: proposals of the groupe de Curiethérapie de la SFRO].
Peiffert D; Hannoun-Lévi JM; Oldrini S; Brunaud C
Cancer Radiother; 2014 Oct; 18(5-6):441-6. PubMed ID: 25218567
[TBL] [Abstract][Full Text] [Related]
2. Dose rate in brachytherapy using after-loading machine: pulsed or high-dose rate?
Hannoun-Lévi JM; Peiffert D
Cancer Radiother; 2014 Oct; 18(5-6):437-40. PubMed ID: 25195117
[TBL] [Abstract][Full Text] [Related]
3. [Brachytherapy in France: current situation and economic outlook due to the unavailability of iridium wires].
Le Vu B; Boucher S
Cancer Radiother; 2014 Oct; 18(5-6):458-60. PubMed ID: 25195115
[TBL] [Abstract][Full Text] [Related]
4. [Pulsed-dose rate brachytherapy in cervical cancers: why, how?].
Mazeron R; Dumas I; Martin V; Martinetti F; Benhabib-Boukhelif W; Gensse MC; Chargari C; Guemnie-Tafo A; Haie-Méder C
Cancer Radiother; 2014 Oct; 18(5-6):447-51. PubMed ID: 25155782
[TBL] [Abstract][Full Text] [Related]
5. Interstitial brachytherapy for lip carcinomas: Comparison between Ir-192 low-dose-rate and high-dose-rate treatment.
Cuenin M; Salleron J; Peiffert D; Meknaci É; Gallet P; Abushama Y; Py JF; Renard S
Cancer Radiother; 2024 Apr; 28(2):145-151. PubMed ID: 38072744
[TBL] [Abstract][Full Text] [Related]
6. [Brachytherapy in France in 1995. Final results of the national survey].
Peiffert D; Simon JM; Baillet F
Cancer Radiother; 1998; 2(3):304-9. PubMed ID: 9749130
[TBL] [Abstract][Full Text] [Related]
7. [Economic assessment of pulsed dose-rate (PDR) brachytherapy with optimized dose distribution for cervix carcinoma].
Remonnay R; Morelle M; Pommier P; Haie-Meder C; Quetin P; Kerr C; Delannes M; Castelain B; Peignaux K; Kirova Y; Romestaing P; Williaume D; Krzisch C; Thomas L; Lang P; Baron MH; Cussac A; Lesaunier F; Maillard S; Barillot I; Charra-Brunaud C; Carrère MO; Peiffert D
Cancer Radiother; 2010 Jun; 14(3):161-8. PubMed ID: 20206571
[TBL] [Abstract][Full Text] [Related]
8. American Brachytherapy Society-Groupe Européen de Curiethérapie-European Society of Therapeutic Radiation Oncology (ABS-GEC-ESTRO) consensus statement for penile brachytherapy.
Crook JM; Haie-Meder C; Demanes DJ; Mazeron JJ; Martinez AA; Rivard MJ
Brachytherapy; 2013; 12(3):191-8. PubMed ID: 23453681
[TBL] [Abstract][Full Text] [Related]
9. Monte Carlo study of the dose rate distributions for the Ir2.A85-2 and Ir2.A85-1 Ir-192 afterloading sources.
Granero D; Pérez-Calatayud J; Ballester F
Med Phys; 2008 Apr; 35(4):1280-7. PubMed ID: 18491521
[TBL] [Abstract][Full Text] [Related]
10. [Brachytherapy in France in 2020: State of the art and perspectives from the Groupe curiethérapie de la SFRO].
Hannoun-Lévi JM; Chand MÈ; Blanchard P; Chargari C; Escande A; Pierrat N; Pommier P; Peiffert D
Cancer Radiother; 2020 Dec; 24(8):876-881. PubMed ID: 32576437
[TBL] [Abstract][Full Text] [Related]
11. [Development and perspectives of brachytherapy in France].
Peiffert D; Hannoun-Lévi JM
Cancer Radiother; 2013 Apr; 17(2):76-80. PubMed ID: 23583231
[TBL] [Abstract][Full Text] [Related]
12. [Guidelines for external radiotherapy and brachytherapy: introduction to the 2nd edition. Société française de radiothérapie oncologique (SFRO)].
Mahé MA; Barillot I; Chauvet B
Cancer Radiother; 2014 Oct; 18(5-6):356-9. PubMed ID: 25199866
[TBL] [Abstract][Full Text] [Related]
13. [New calculation algorithms in brachytherapy for iridium 192 treatments].
Robert C; Dumas I; Martinetti F; Chargari C; Haie-Meder C; Lefkopoulos D
Cancer Radiother; 2018 Jun; 22(4):319-325. PubMed ID: 29784552
[TBL] [Abstract][Full Text] [Related]
14. [How to prepare the brachytherapy of the future].
Hannoun-Lévi JM; Peiffert D
Cancer Radiother; 2013 Oct; 17(5-6):395-9. PubMed ID: 23993062
[TBL] [Abstract][Full Text] [Related]
15. Perspectives of brachytherapy: patterns of care, new technologies, and "new biology".
Guedea F
Cancer Radiother; 2014 Oct; 18(5-6):434-6. PubMed ID: 25175344
[TBL] [Abstract][Full Text] [Related]
16. Prostate cancer brachytherapy: SFRO guidelines 2021.
Pommier P; Ferré M; Blanchard P; Martin É; Peiffert D; Robin S; Hannoun-Lévi JM; Marchesi V; Cosset JM
Cancer Radiother; 2022; 26(1-2):344-355. PubMed ID: 34955422
[TBL] [Abstract][Full Text] [Related]
17. [In vivo dosimetry in interstitial "low dose rate" afterloading therapy with Ir-192 seeds exemplified with head-neck tumors].
Sadat Khonsari A; Grabenbauer G; Müller RG; Säbel M
Strahlenther Onkol; 1991 Jul; 167(7):407-11. PubMed ID: 1858017
[TBL] [Abstract][Full Text] [Related]
18. Best practice in brachytherapy.
Hannoun-Lévi JM; Chargari C; Blanchard P; Pommier P; Ollivier L; Ferré M; Peiffert D
Cancer Radiother; 2022; 26(1-2):29-33. PubMed ID: 34953690
[TBL] [Abstract][Full Text] [Related]
19. Cervix cancer brachytherapy: high dose rate.
Miglierini P; Malhaire JP; Goasduff G; Miranda O; Pradier O
Cancer Radiother; 2014 Oct; 18(5-6):452-7. PubMed ID: 25151650
[TBL] [Abstract][Full Text] [Related]
20. [Templates for curietherapy of the oral cavity and their dosimetric use].
Pizzi G; Fongione S; Mandoliti G; Beorchia A; Contento G; Malisan MR
Radiol Med; 1989 Dec; 78(6):620-5. PubMed ID: 2626556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
